Company intelligence / Profile preview
Inosi Therapeutics
Melbourne, Victoria, Australiainositherapeutics.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Inosi Therapeutics is developing first-in-class small molecule inhibitors aimed at reversing fibrosis by targeting a central pathway involved in both fibrosis and inflammation. The company’s technology is based on research from Monash University, with support from IP Group and BioCurate. As of the most recent updates, their programs are pre-clinical; no clinical trial results have been reported yet.
- Therapeutic areas
- Other
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Monash University/Monash InnovationSt Vincent’s Institute of Medical ResearchFlorey Institute of Neuroscience and Mental HealthIP Group Australia (investor/partner)BioCurate (investor/partner)
Beyond the preview
Go deeper on Inosi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inosi Therapeutics.